


Study 1 showed that Move Free® Advanced showed efficacy within one week. This second study was performed to further explore the efficacy of Move Free® Advanced within 7 days as compared to a leading analgesic for joint discomfort and function. A preliminary, randomized, double-blind, double-dummy, active-comparator, parallel-group clinical study was conducted in 130 subjects with joint discomfort. Global Clinicals, Inc. conducted the study in Los Angeles in 2006-2008 after IRB approval. The average age of the subjects was 57 ± 10 years. The groups included an Active Comparator group (Group 1) and Move Free® Advanced (Group 2). WOMAC and SF-36v2 questionnaires were determined at baseline, 7 days and 56 days (for a subset of subjects). VAS scores were obtained at 0, 1, 2, 3, 4, 5, 6 and 7 days.

Group 2 showed statistically significant within-group improvements in all WOMAC and SF-36 scores on day 7. Total WOMAC scores improved 30% in the Group 2. Comparison between groups did not show significant differences, meaning that Group 2 was equivalent to Group 1 for improving joint comfort and function after 7 days. Subjects rated their joint discomfort compared to the first day of the study using VAS scales. Single factor ANOVA showed that Group 2 was significantly different from baseline at day 3 ($p < 0.05$). This significance steadily increased until day 7 ($p = 0.0103$). Thus Group 2 started working on joint discomfort in less than 7 days by WOMAC scores and VAS scales.

Two independently conducted, double-blind, controlled human clinical studies using Move Free® Advanced were conducted two years apart on opposite sides of the continent, lending robustness to the results. Both studies found essentially similar results for improvements in joint comfort and joint function after one week, with continued improvement at 8 weeks. Study protocols utilized the recommended and acceptable outcome measurements for joint health, and sample sizes were determined by statistical power analysis. Results from a first preliminary study were confirmed and extended to shorter time periods in a larger second study. Thus, Move Free® Advanced has been clinically tested and shown to improve joint health. The graph below shows the improvement in joint comfort (WOMAC scores) after 7 days for each study. Results from each study were not significantly different, illustrating the reproducible nature of how the formulation affects joint health.



Note: A decrease in WOMAC scores indicates an improvement. Clinical significance (clinical response) has been set at a 20% or greater decrease in WOMAC scores (Clegg 2006). P value indicates a significant difference from baseline values.

REFERENCES

Bucci 2005a; Bucci 2005b; Bucci 2005c; Turpin 2006; Schiff Nutrition International, recently completed human clinical study, Los Angeles, 2008

THESE STATEMENTS HAVE NOT BEEN EVALUATED BY THE FOOD AND DRUG ADMINISTRATION.
THIS PRODUCT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE OR PREVENT ANY DISEASE.